MapLight Therapeutics, Inc.
Financials
Valuation Metrics
MapLight Therapeutics, Inc.'s Market Cap is $321M. At end of 2025 it was $728M. Ranked #2892 of 3,116 in US market (top 93%), #1301 of 1,472 on NASDAQ (top 88%), #233 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 88%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $321M | US#2,892/3,116 Sec#233/265 |
| Revenue | $0.00 | US#2,859/3,116 Sec#193/265 |
| Net Income | $-230M | US—/3,116 Sec—/265 |
| Total Assets | $368M | US#2,859/3,116 Sec#194/265 |
| Net Assets | $348M | US#2,440/3,116 Sec#147/265 |
| Employees | 133 | US#2,562/3,116 Sec#156/265 |
| Value | ||
| P/B | 0.92x | US#348/3,116 Sec#19/265 |
| FCF Yield | -54.51% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROE | -65.99% | US#2,729/3,116 Sec#182/265 |
| ROA | -62.39% | US#3,015/3,116 Sec#232/265 |
| Financial Health | ||
| Debt Ratio | 5.76% | US#46/3,116 Sec#19/265 |
| Total Debt | $2M | US#2,947/3,116 Sec#234/265 |
| FCF | $-175M | US#2,754/3,116 Sec#197/265 |
| Cash | $72M | US#2,411/3,116 Sec#201/265 |
| Current Ratio | 16.52x | US#143/3,116 Sec#39/265 |
| Performance | ||
| 1Y Return | -58.79% | US#2,911/3,116 Sec#240/265 |
| 1M Return | -25.71% | US#2,961/3,116 Sec#244/265 |
| From 52W High | -81.28% | US#3,062/3,116 Sec#252/265 |
| 1Y MDD | -80.98% | US#3,044/3,116 Sec#248/265 |
| Trading | ||
| Volume | 335,469 shares | US#2,772/3,116 Sec#253/265 |
| Trading Value | $3M | US#3,003/3,116 Sec#252/265 |
| Per Share | ||
| EPS | $-5.42 | US—/3,116 Sec—/265 |
| BPS | $8.21 | US#1,975/3,116 Sec#84/265 |
Company Info
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing innovative treatments for individuals grappling with severe central nervous system (CNS) disorders. Its pipeline features several promising therapeutic candidates: ML-007C-MA, a fixed-dose combination of an M1/M4 muscarinic agonist, is being advanced to address symptoms of schizophrenia and Alzheimer's disease psychosis. Additionally, the company is investigating ML-004 for its potential to alleviate social communication deficits and irritability associated with autism spectrum disorder, while ML-021 is designed to target motor impairments seen in Parkinson's disease. Furthermore, ML-009, a G-protein-coupled receptor 52 positive allosteric modulator, is under development for conditions involving hyperactivity, impulsivity, and agitation. Beyond its drug portfolio, MapLight has also established a proprietary platform focused on identifying neural circuits fundamentally linked to disease and then precisely modulating these circuits for therapeutic benefit. Established in 2018 under its former name, Alvarado Therapeutics, Inc., the company adopted the MapLight Therapeutics, Inc. identity in August 2019. Based in Redwood City, California, it operates as a subsidiary of Catalyst4, Inc.